Xcout Intel
AAVantgarde Bio
AAVantgarde Bio is an Italian biotechnology company developing adeno-associated virus (AAV) gene therapies for rare genetic diseases, including conditions caused by genes too large to fit into a single AAV vector. Its technology uses dual-AAV approaches to deliver larger therapeutic genes, serving patients with serious inherited disorders and the clinicians who treat them.
Subscribe to see AAVantgarde Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AAVantgarde Bio at a glance
AAVantgarde Bio is a biotech company headquartered in Italy. Its most recent funding round, Series B, raised $141M in November 2025. Xcout tracks 3 named people at AAVantgarde Bio, including Megan Zoschg Canniere (Chief Regulatory & Quality Officer). Xcout recorded 1 job posting from AAVantgarde Bio in the last 90 days.
AAVantgarde Bio leadership
- Megan Zoschg CanniereChief Regulatory & Quality Officer
- Alberto AuricchioFounder, AAVANTGARDE / CSO
- Philip LaoSenior Vice President Business Development
AAVantgarde Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $141M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at AAVantgarde Bio
Xcout recorded 1 job posting from AAVantgarde Bio in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see AAVantgarde Bio's hiring signals →
Investors
AAVantgarde Bio competitors
A few of AAVantgarde Bio's closest competitors — see the full list of competitors and alternatives →
AskBio is a clinical-stage gene therapy company that develops adeno-associated virus (AAV) gene therapies to treat genetic and complex disorders. The company focuses on advancing genetic medicine through its proprietary technology platforms, manufacturing processes, and clinical trials.
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Get AAVantgarde Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AAVantgarde Bio in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access